World-class claim needs independent proof
Keith Bernard says President Ali’s ‘world-class’ praise for New GPC skipped the only test that matters: independent GMP inspection.
Dear Editor,
The recent visit by President Dr. Mohamed Irfaan Ali to New Guyana Pharmaceutical Corporation (New GPC) at Farm, East Bank Demerara, and his subsequent description of the facility as operating at “world-class standards” raise serious questions about his briefing and the effectiveness of pharmaceutical regulatory oversight in Guyana.
These concerns were first brought to my attention by a longtime friend who has been a practising pharmacist for more than three decades. His professional experience prompted me to examine the photographs accompanying the President’s public statement and consider them against the established requirements governing pharmaceutical manufacturing.
While I support the development of Guyana’s pharmaceutical manufacturing industry, the President’s endorsement appears premature and raises questions about whether he was adequately advised on the stringent requirements governing pharmaceutical manufacturing.
Ironically, the photographs accompanying his own public statement raise concerns about the very standards he praised. The images appear to show individuals in pharmaceutical manufacturing areas, prompting questions about appropriate protective clothing, face coverings, gowning procedures, access control and contamination-prevention practices. These are not minor administrative details; they are fundamental safeguards in pharmaceutical manufacturing.
The United States Food and Drug Administration’s Title 21 Code of Federal Regulations, Parts 210 and 211, establishes comprehensive Current Good Manufacturing Practice (cGMP) requirements. In particular, Sections 211.28, 211.42, 211.56 and 211.67 address personnel hygiene and protective clothing, facility design, sanitation, and equipment cleaning and maintenance. These requirements are intended to prevent contamination and ensure that pharmaceutical products consistently meet established quality standards.
Guyana has its own legal obligations under the Food and Drugs Act, Chapter 34:03, and the Food and Drugs Regulations 1977.1 Regulation 117 establishes specific requirements for pharmaceutical manufacturing facilities and operations, including sanitary conditions, personnel practices, equipment cleaning, raw material testing, finished product testing and manufacturing records. Particularly important is Regulation 117(2)(e), which requires parenteral drug filling and aseptic processes to be conducted in a separate, enclosed area designed and operated to prevent contamination.
The photographs do not, by themselves, establish regulatory violations. However, they raise legitimate questions that warrant examination by the relevant regulatory authorities. Were the individuals depicted following the appropriate procedures for the particular manufacturing environments they entered? Were contamination-control protocols maintained throughout the President’s visit?
These concerns become even more significant in light of the President’s announcement of New GPC’s plans to manufacture intravenous fluids and vaccines. Products administered directly into the bloodstream demand stringent sterility assurance, environmental monitoring, endotoxin control, validated manufacturing processes and rigorous quality testing. Vaccine manufacturing also requires specialized biological manufacturing controls and regulatory oversight. Existing pharmaceutical production capabilities should not automatically be interpreted as evidence of readiness to manufacture these more complex products.
The fundamental question is whether New GPC’s operations have been independently assessed and verified against the applicable regulatory requirements. When was the company’s last comprehensive Good Manufacturing Practices inspection? What deficiencies, if any, were identified, and have corrective actions been independently verified? Does its quality control unit have the necessary independence and authority to reject products that fail established specifications? Are its manufacturing processes, laboratory controls and environmental conditions properly validated and documented?
The FDA regulations provide an internationally recognized benchmark, although they are not automatically binding on every manufacturer operating in Guyana. Guyana’s own legislation, however, is binding and must be consistently enforced.
Modern equipment, impressive production facilities, artificial intelligence and ambitious expansion plans do not establish pharmaceutical quality. Nor does a presidential tour constitute a regulatory inspection. A management presentation is not independent verification of compliance.
The President may have been ill-advised in accepting the company’s presentation as sufficient evidence of world-class manufacturing standards without first seeking independent confirmation from the Government Analyst-Food and Drug Department. The responsibility for determining regulatory compliance rests with the competent regulatory authorities, not company management or visiting politicians.
I therefore call on the Minister of Health and the Government Analyst-Food and Drug Department to publicly clarify New GPC’s current GMP compliance status, disclose the findings of its most recent inspection, and indicate whether any outstanding deficiencies or corrective actions remain.
Guyana should be proud of its pharmaceutical manufacturing capacity, but national pride and commercial interests must never supersede public health. The safety, quality, purity and efficacy of medicines must be beyond question.
A presidential endorsement is not a GMP certification. A factory tour is not a regulatory inspection. And world-class standards must be demonstrated through independent inspections and documented compliance, not merely proclaimed.
Sincerely,Keith Bernard
References
1 source- 1Food and Drugs Act (Cap. 34;03).leap.unep.org